NASDAQ : MLYS
Mineralys Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 18.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.61B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.61B |
| Enterprise Value | 1.04B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 88.41M |
| Shares Outstanding | 88.41M |
| Shares Change (YoY) | +46.24% |
| Shares Change (QoQ) | +2.28% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 90.92% |
| Float | 66.60M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 97.24 |
| PB Ratio | 2.92 |
| P/TBV Ratio | 2.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 34.46 |
| Quick Ratio | 34.24 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -80.88% |
| Return on Assets (ROA) | -46.18% |
| Return on Invested Capital (ROIC) | -48.18% |
| Return on Capital Employed (ROCE) | -57.17% |
| Weighted Average Cost of Capital (WACC) | 7.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.60M |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -54.71% |
| 50-Day Moving Average | 24.78 |
| 200-Day Moving Average | 26.99 |
| Relative Strength Index (RSI) | 29.89 |
| Average Volume (20 Days) | 1,532,438 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.44M |
| Short Previous Month | 7.81M |
| Short % of Shares Out | 8.41% |
| Short % of Float | 11.17% |
| Short Ratio (days to cover) | 4.98 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -370.79M |
| Pretax Income | -349.58M |
| Net Income | -349.58M |
| EBITDA | -370.75M |
| EBIT | -370.79M |
| Earnings Per Share (EPS) | -$4.38 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 661.41M |
| Total Debt | 97.62M |
| Net Cash | 563.80M |
| Net Cash Per Share | $6.38 |
| Equity (Book Value) | 550.92M |
| Book Value Per Share | 6.24 |
| Working Capital | 646.48M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -138.79M |
| Capital Expenditures | -15,000 |
| Depreciation & Amortization | 39,000 |
| Net Borrowing | 97.50M |
| Free Cash Flow | -138.80M |
| FCF Per Share | -$1.57 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -46.24% |
| Shareholder Yield | -46.24% |
| Earnings Yield | -24.07% |
| FCF Yield | -8.64% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $45.22 |
| Price Target Difference | 148.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |